

## HbA<sub>1c</sub> Levels in Controlled Diabetics with and without Iron Deficiency Anemia: A Tertiary Care Experience

Zoya Khatri<sup>1</sup> , Anita Chalak<sup>2</sup> , Megha Bangar<sup>3</sup> , Shalini Maksane<sup>4</sup>  , Supriya Khillare<sup>5</sup> 

<sup>1</sup> Seth GS Medical college and KEM Hospital (Batch 2018), Parel Mumbai, India

<sup>2</sup> Department of Biochemistry, Seth GS Medical college and KEM Hospital, Parel, Mumbai, India

<sup>3</sup> Department of Biochemistry, D.Y Patil Medical College, Navi Mumbai, India

<sup>4</sup> MGM Medical College, Hospital and Research Centre, Vashi, Navi Mumbai, India

<sup>5</sup> Department of Biochemistry, D Y Patil Medical College and Hospital, Nerul, Navi Mumbai, India

### Article Info

#### Article type:

Original Article

#### Article History:

Received: Nov. 28, 2024

Revised: Jul. 17, 2025

Accepted: Sep. 01, 2025

Published Online: Oct. 01, 2025

#### ✉ Correspondence to:

Shalini Maksane  
MGM Medical College,  
Hospital and Research Centre,  
Vashi, Navi Mumbai, India

#### Email:

shalinidabi24@gmail.com

### ABSTRACT

**Introduction:** Glycated hemoglobin (HbA<sub>1c</sub>) is widely used to assess long-term glycemic control in diabetic patients. However, non-glycemic factors such as iron deficiency anemia (IDA) may alter HbA<sub>1c</sub> levels, potentially affecting its accuracy. This study aimed to evaluate the effect of IDA on HbA<sub>1c</sub> levels in diabetic patients with controlled fasting plasma glucose.

**Materials & Methods:** An analytical cross-sectional study was conducted on 80 diabetic patients aged 18–60 years, divided equally into IDA and non-IDA groups. IDA diagnosis was based on hemoglobin levels, red blood cell indices, serum ferritin, serum iron, and total iron-binding capacity (TIBC). HbA<sub>1c</sub> was measured using high-performance liquid chromatography; while fasting plasma glucose was determined by the glucose oxidase-peroxidase method.

**Results:** Mean HbA<sub>1c</sub> levels were  $6.1 \pm 0.59\%$  in the IDA group and  $6.2 \pm 0.73\%$  in the non-IDA group, with no statistically significant difference ( $p = 0.6143$ ). Age and gender showed more influence on HbA<sub>1c</sub> values than IDA status. No significant correlation was found between HbA<sub>1c</sub> and hematological or iron parameters within the IDA group.

**Conclusion:** Iron deficiency anemia does not significantly affect HbA<sub>1c</sub> levels in diabetic patients with well-controlled fasting glucose. Therefore, HbA<sub>1c</sub> remains a reliable marker for glycemic control in these patients. Clinicians should still interpret HbA<sub>1c</sub> cautiously in anemic individuals and consider additional assessments if necessary.

**Keywords:** glycated hemoglobin, anemia, iron deficiencies, diabetes mellitus, blood glucose

### ➤ Cite this paper

Khatri Z, Chalak A, Bangar M, Maksane S, Khillare S. HbA<sub>1c</sub> Levels in Controlled Diabetics with and without Iron Deficiency Anemia: A Tertiary Care Experience. *J Bas Res Med Sci*. 2025; 12(4):32-40.

## Introduction

HbA<sub>1c</sub>, the major component of HbA<sub>1</sub>, is formed by the glycation of terminal valine on the beta chain of hemoglobin (1, 2). Its levels are directly proportional to plasma glucose concentrations and remain stable, reflecting the glycemic status of a patient over the preceding 8–12 weeks (3). HbA<sub>1c</sub> is widely used for monitoring diabetes control and has been recognized since 2010 as a diagnostic and screening tool for high-risk individuals. The World Health Organization (WHO) supports its use for diagnosing diabetes (4). However, HbA<sub>1c</sub> levels can be influenced by factors unrelated to glycemia, particularly conditions that affect red blood cell (RBC) turnover. These include hemoglobinopathies, hemolytic anemia, pregnancy, blood loss, and uremia (5). Iron deficiency anemia (IDA) is the most common form of anemia both globally and in India (6). Diabetes prevalence is increasing rapidly in India, with a 2023 ICMR study reporting an 11.4% diabetes rate, higher in urban than rural populations (7).

Research investigating the impact of IDA on HbA<sub>1c</sub> has shown inconclusive results (8, 9). Some studies imply that people who don't get enough iron have higher HbA<sub>1c</sub> levels, especially if their glucose levels are normal or pre-diabetic (10,11). However, other studies do not discover this link in people who already have diabetes (12). In light of these contradictory data, it is essential to delineate the effect of iron deficiency on HbA<sub>1c</sub>, excluding the confounding variable of variable or uncontrolled blood glucose levels. Consequently, this research only included diabetic individuals with regulated glycemia (fasting plasma glucose <126 mg/dL). This method was used to guarantee that any fluctuations seen in HbA<sub>1c</sub> levels may be more reliably ascribed to iron status rather than to changes in glycemic control. This strategy will improve the study's internal validity by reducing the variability caused by high blood sugar. It will also help us better understand how IDA could affect HbA<sub>1c</sub> levels in people with diabetes.

So, the aim of the present study was to evaluate the effect of iron deficiency anemia (IDA) on HbA<sub>1c</sub> levels in diabetic individuals with controlled glycemic status and to determine whether IDA significantly alters HbA<sub>1c</sub> values independent of plasma glucose levels.

## Materials and methods

### *Study Design*

An analytical cross-sectional study was conducted from May to July 2021 by the Biochemistry Department in collaboration with Pathology and Endocrinology Departments at a tertiary care centre.

### *Setting and Participants*

The study included diabetic individuals with controlled glycemic status, defined as fasting plasma glucose (FPG) levels below 126 mg/dL. To identify cases of iron deficiency anemia (IDA), participants were required to have hemoglobin levels below 13 g/dL in males and below 12 g/dL in females, as per WHO guidelines. Additional hematological indicators included hypochromic and microcytic red blood cell indices, specifically a mean corpuscular hemoglobin (MCH) less than 26 pg/cell and a mean corpuscular volume (MCV) less than 80 fL, along with a peripheral smear showing a microcytic hypochromic picture. Biochemical confirmation of IDA included serum ferritin levels under 30 ng/mL and serum iron levels less than 50 µg/dL in females and less than 65 µg/dL in males. Individuals were excluded if they had fasting plasma glucose above 126 mg/dL or random plasma glucose above 200 mg/dL, were taking iron supplementation, or if they had a history of conditions such as significant blood loss, hemoglobinopathies, hypothyroidism, coagulation disorders, or hemolytic anemia. Pregnant women and those with abnormal renal function, as indicated by elevated blood urea or serum creatinine, were also excluded. Female participants with amenorrhea for more than two months underwent urinary pregnancy testing, and those testing positive were excluded. Additionally, participants with a

reticulocyte count greater than 2.5% were not included in (13).

### Sample Size

Based on Christy et al. (10), using SD = 1.4 and d = 1.22 with 5% type I error and 80% power, the sample size per group was calculated to be 21. Adding 10% for possible dropout, 24 participants per group is calculated. The study should include a total of 48 participants. But to increase the power of the study, we decided to select 40 participants per group.

### Measurements & Validity and Reliability

Convenience sampling was used to recruit 80 diabetic patients (aged 18–60). Participants were divided into two groups: Group 1 (n=40) included diabetic patients with IDA, and Group 2 (n=40) included diabetic patients without IDA. HbA<sub>1c</sub> was measured by high-performance liquid chromatography using the Bio-Rad D-10 analyzer. Glucose was measured by the glucose oxidase-peroxidase method. Additional hematological data (e.g., serum ferritin, MCH, MCHC, MCV) were retrieved from previous lab records.

### Statistical and Data Analysis

Data were analysed using GraphPad Prism. Quantitative data were expressed as mean  $\pm$  SD, and group comparisons were made using unpaired t-tests. Categorical variables were analysed using the chi-square test. A p-value  $<0.05$  was considered statistically significant.

### Results

The average age of the group was 49.99 years, with 39 women and 41 men. Seventy percent of IDA patients were female. Table 1 shows a comparison of several demographic and biochemical factors

between diabetic individuals with iron deficiency anemia (IDA) and those without IDA (N = 40 in each group). The evaluated criteria include diabetic indices, hematological indices, and iron profile indicators. There were no statistically significant variations in fasting plasma glucose (FPG) and glycated hemoglobin (HbA<sub>1c</sub>) levels between the two groups (p = 0.7998 and p = 0.6143, respectively), indicating similar glycemic management in diabetic patients regardless of IDA status. Nonetheless, significant discrepancies were seen in hematological and iron profile data.

The hemoglobin levels in IDA patients ( $11.4 \pm 0.94$  g/dl) were significantly lower than those in non-IDA patients ( $14.4 \pm 1.42$  g/dl), with a p-value of less than 0.0001. The IDA group had considerably lower red blood cell indices, such as mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), and mean corpuscular hemoglobin concentration (MCHC) (p  $< 0.0001$  for all). This is in line with the microcytic hypochromic character of iron deficiency anemia. On the other hand, the red cell distribution width (RDW) was much greater in the IDA group ( $14.6 \pm 2.21\%$ ) than in the non-IDA group ( $13.4 \pm 1.24\%$ , p = 0.0267). This shows anisocytosis, which is a symptom of iron-deficient erythropoiesis.

The iron profile analysis confirmed the diagnosis of IDA in the afflicted patients. In patients with IDA, serum ferritin and serum iron levels were considerably lower ( $28.1 \pm 1.61$  ng/dl and  $47.8 \pm 7.57$  mcg/dl, respectively) than in patients without IDA ( $94.8 \pm 31.99$  ng/dl and  $73.4 \pm 10.90$  mcg/dl), with p-values  $< 0.0001$ . Total iron-binding capacity (TIBC) was considerably higher in IDA patients ( $415.0 \pm 25.45$  mcg/dl vs.  $324.2 \pm 10.14$  mcg/dl, p  $< 0.0001$ ), which further supports the iron-deficient status.

**Table 1.** Comparison of Haematological and Glycemic Parameters Between Controlled Diabetic Patients With and Without IDA.

Parameter (Normal range) [13]	Diabetics with IDA (N = 40) Mean $\pm$ SD	Diabetics without IDA (N = 40) Mean $\pm$ SD	P value
Fasting Plasma Glucose (mg/dL) ( $<100$ )	$112.7 \pm 12.05$	$113.6 \pm 14.23$	0.7998
HbA <sub>1c</sub> (%) ( $<5.6\%$ )	$6.1 \pm 0.59$	$6.2 \pm 0.73$	0.6143

Hemoglobin (g/dL) (12.0–17.2)	11.4 ± 0.94	14.4 ± 1.42	<0.0001*
MCV (fL) (80–100)	77.7 ± 2.84	89.3 ± 3.91	<0.0001*
MCH (pg) (26–33)	24.6 ± 1.05	30.6 ± 1.80	<0.0001*
MCHC (g/dL) (33–37)	32.1 ± 1.83	34.2 ± 0.92	<0.0001*
RDW (%) (11.5–14.5)	14.6 ± 2.21	13.4 ± 1.24	0.0267
Serum Ferritin (ng/mL) (30–100)	28.1 ± 1.61	94.8 ± 31.99	<0.0001*
Serum Iron (μg/dL) (>50)	47.8 ± 7.57	73.4 ± 10.90	<0.0001*
TIBC (μg/dL) (300–360)	415.0 ± 25.45	324.2 ± 10.14	<0.0001*

\*Statistically significant ( $p < 0.05$ ). Values are presented as mean ± standard deviation (SD). FPG = Fasting Plasma Glucose, HbA<sub>1c</sub> = Glycated Hemoglobin, MCV = Mean Corpuscular Volume, MCH = Mean Corpuscular Hemoglobin, MCHC = Mean Corpuscular Hemoglobin Concentration, RDW = Red Cell Distribution Width, TIBC = Total Iron-Binding Capacity

Tables 2a, b, and c present the mean HbA<sub>1c</sub> levels among 80 diabetic patients, stratified by age, gender, and presence of iron deficiency anemia (IDA). Overall, patients older than 50 years exhibited higher HbA<sub>1c</sub> levels ( $6.33 \pm 0.66\%$ ) compared to those under 50 years ( $5.96 \pm 0.61\%$ ), indicating poorer glycemic control with advancing age. When analyzed by gender within age groups, both males and females showed an increase in HbA<sub>1c</sub> with age, although the rise was more pronounced in males—from  $6.05 \pm 0.68\%$  in those under 50 to  $6.59 \pm 0.68\%$  in those over 50. In contrast, the corresponding increase in females was from  $5.95 \pm 0.61\%$  to  $6.22 \pm 0.49\%$ . This suggests a gender-related variation in glycemic trends, with older males having the highest HbA<sub>1c</sub> levels overall.

When stratified by IDA status, non-IDA patients had slightly higher mean HbA<sub>1c</sub> levels ( $6.27 \pm 0.73\%$ ) compared to IDA patients ( $6.17 \pm 0.59\%$ ). Among females, the IDA group had higher HbA<sub>1c</sub> ( $6.11 \pm 0.57\%$ ) than the non-IDA group ( $5.94 \pm 0.59\%$ ), whereas among males, HbA<sub>1c</sub> was higher in the non-IDA group ( $6.40 \pm 0.75\%$ ) compared to those with IDA ( $6.31 \pm 0.66\%$ ). Further, age-based comparison within IDA and non-IDA groups showed that HbA<sub>1c</sub> increased with age regardless of anemia status. Notably, non-IDA patients over 50 years recorded the highest mean HbA<sub>1c</sub> ( $6.56 \pm 0.67\%$ ), reinforcing the influence of age on glycemic control. While some differences in HbA<sub>1c</sub> across groups appear modest, the patterns suggest that age and gender exert stronger effects on HbA<sub>1c</sub> than IDA status alone.

**Table 2.** HbA<sub>1c</sub> Stratified by Age, Gender, and IDA Status in Controlled Diabetic Patients.

a) By Age and Gender			b) By IDA and Gender			c) By Age and IDA Status		
Group	<50 Years Mean ± SD	>50 Years Mean ± SD	Group	IDA Mean ± SD	Non-IDA Mean ± SD	Group	<50 Years Mean ± SD	>50 Years Mean ± SD
Total (N = 80)	5.96 ± 0.61	6.33 ± 0.66	Total (N = 80)	6.17 ± 0.59	6.27 ± 0.73	IDA (N = 40)	6.01 ± 0.58	6.31 ± 0.58
Females (N = 39)	5.95 ± 0.61	6.22 ± 0.49	Females (N = 39)	6.11 ± 0.57	5.94 ± 0.59	Non-IDA (N = 40)	5.98 ± 0.68	6.56 ± 0.67
Males (N = 41)	6.05 ± 0.68	6.59 ± 0.68	Males (N = 41)	6.31 ± 0.66	6.40 ± 0.75			

Table 3 shows the connection analysis of HbA<sub>1c</sub> levels and several blood parameters in people with diabetes who also have iron deficiency anemia (IDA). None of the factors exhibited a statistically significant

connection with HbA<sub>1c</sub> levels ( $p > 0.05$ ). Among the factors examined, serum iron had the most robust positive connection with HbA<sub>1c</sub> ( $r = +0.34$ ), but this correlation did not achieve statistical significance ( $p$

= 0.10). There was a modest negative association between hemoglobin concentration and HbA<sub>1c</sub> ( $r = -0.25$ ,  $p = 0.24$ ), which means that when hemoglobin levels go up, HbA<sub>1c</sub> levels may go down. Likewise, red cell distribution width (RDW) and mean corpuscular hemoglobin concentration (MCHC) exhibited minor negative relationships ( $r = -0.24$  and  $-0.23$ , respectively), however these findings were not statistically significant. Other parameters, such as serum ferritin ( $r = -0.13$ ), total iron-binding capacity (TIBC) ( $r = +0.07$ ), mean corpuscular volume (MCV) ( $r = +0.09$ ), and mean corpuscular hemoglobin

(MCH) ( $r = -0.12$ ), exhibited negligible correlations with HbA<sub>1c</sub>, with all  $p$ -values exceeding 0.05, signifying a lack of significant statistical association. Age exhibited no significant correlation with HbA<sub>1c</sub> levels ( $r = +0.18$ ,  $p = 0.41$ ). In general, our results indicate that among diabetes patients with iron deficiency anemia, changes in hematological parameters, such as iron status, do not have a significant effect on HbA<sub>1c</sub> levels. Nonetheless, the identified tendencies, especially with serum iron and hemoglobin, need further examination in more extensive cohorts.

**Table 3.** Correlation of HbA<sub>1c</sub> with Hematological Parameters in Diabetic Patients with IDA.

Parameter	Correlation Coefficient (r)	P value
Age (years)	+0.18	0.41
Hemoglobin (g/dL)	-0.25	0.24
Serum Iron (µg/dL)	+0.34	0.10
Serum Ferritin (ng/mL)	-0.13	0.56
TIBC (µg/dL)	+0.07	0.73
MCV (fL)	+0.09	0.69
MCH (pg)	-0.12	0.58
MCHC (g/dL)	-0.23	0.28
RDW (%)	-0.24	0.31

## Discussion

The World Health Organization (WHO) endorses HbA<sub>1c</sub> as a key biomarker since it is very reliable, useful, and closely linked to issues connected to diabetes. Nonetheless, other demographic and clinical factors—such as age, gender, ethnicity, genetic predisposition, and specific medical conditions—can affect HbA<sub>1c</sub> levels (14–16).

Anemia is regarded as one of the most prevalent variables affecting HbA<sub>1c</sub> levels. Many research have looked at this link, which seems to rely on what caused the anemia in the first place. Iron deficiency anemia is the most prevalent form of nutritional anemia. It accounts for almost 50% of the global load. There has been a recent surge of interest in the scientific community about the examination of HbA<sub>1c</sub> values in commonly seen anemias, such as iron deficiency anemia (IDA) (9). The precise processes remain ambiguous, and the ideas suggested

by various investigations to far are speculative. This encouraged us to do a research to assess the effect of IDA on HbA<sub>1c</sub> levels in diabetes individuals with regulated glucose. In line with previous studies by Mitchell et al. (17) and Van Heyningen et al. (18), our results indicated no significant difference in HbA<sub>1c</sub> levels between managed diabetic individuals with and without IDA, and the absence of association remained unaccounted for. Grossman et al. (19) found that HbA<sub>1c</sub> levels were related to several things, such hematocrit, hemoglobin, and dietary variables that cause anemia in older persons. Our results on HbA<sub>1c</sub> levels in well-controlled diabetic individuals, both with and without iron deficiency anemia (IDA), diverge from findings in numerous other studies. A comprehensive review and meta-analysis conducted by Alharbi et al. in 2023 reaffirmed the finding that iron deficiency may cause inaccurately high HbA<sub>1c</sub> values, particularly in those without diabetes. A research conducted in India by



Dutta et al. (21) indicated elevated HbA<sub>1c</sub> levels in people with iron deficiency, suggesting that iron therapy may have corrected these levels.

Changes in the lifetime of red blood cells (RBCs) have a big effect on HbA<sub>1c</sub> levels. For example, RBCs with shorter lifespans have lower HbA<sub>1c</sub> levels even when blood sugar levels are high (22, 23). This corroborates prior research indicating that iron shortage, which extends RBC lifespan, might increase HbA<sub>1c</sub> levels. Moreover, discrepancies in HbA<sub>1c</sub> readings have been ascribed to variations in analytical methodologies (24). When looking at HbA<sub>1c</sub> values, these things should be taken into account. Iron deficiency pathophysiologically impacts the structure and function of hemoglobin. Sinha et al. (9) posited that modified hemoglobin structure in iron deficiency anemia (IDA) may enhance its vulnerability to glycation, irrespective of glucose concentrations. Additionally, iron shortage has been linked to prolonged RBC life resulting from diminished erythropoiesis, which increases Hb glycation over time (25). On the other hand, iron treatment boosts erythropoiesis, which means there are more younger RBCs with less glycation. This lowers HbA<sub>1c</sub> (26). Chronic inflammation, which is frequent in people with diabetes, makes iron metabolism even more difficult. Elevated cytokines, such as interleukin-6 (IL-6), stimulate hepatic hepcidin production, hindering iron uptake and mobilization, which may worsen anemia and influence glycation dynamics (27). Fernandez-Real et al. (28) highlighted the interplay between iron metabolism and diabetes, suggesting that imbalances in iron levels may indirectly influence HbA<sub>1c</sub> measurements. In general, we can say that there might be significant confounders in HbA<sub>1c</sub> tests, as we have shown, not only iron deficiency.

Inconsistent findings among studies may also be caused by differences in the way HbA<sub>1c</sub> is measured. Certain tests, particularly those predicated on charge differentials, may be influenced by modified hemoglobin variants in iron deficiency anemia

(IDA), resulting in erroneous HbA<sub>1c</sub> measurements (29). Our research did not detect a strong link between iron deficiency anemia and HbA<sub>1c</sub> levels in diabetes individuals who were well-controlled. However, these null results are still scientifically important. They challenge established beliefs, augment the current research base, and highlight the intricacy of glycation processes in the context of hematological diseases. Publishing this kind of information is very important for getting a full picture and for improving and informing future research in this area.

No further evaluation was conducted to determine changes in HbA<sub>1c</sub> post-iron treatment. The research only included individuals with regulated glycemia, excluding those with uncontrolled diabetes. Furthermore, the research did not juxtapose HbA<sub>1c</sub> with other glycemic indicators such as fructosamine or glycated albumin. Also, since it was a fundamental research project for undergraduates, it didn't include any complicated theories.

## Conclusion

Further prospective studies are required to observe the impact of iron therapy on HbA<sub>1c</sub> status in larger populations, with emphasis on various confounding factors. However, alternatively, an oral glucose tolerance test could be considered important to avoid misdiagnosing diabetes in all subjects with or without IDA. Clinicians should interpret HbA<sub>1c</sub> cautiously in anemic patients, especially in borderline cases, and consider adjunct markers like fructosamine and glycated albumin that are less influenced by RBC turnover and iron status.

## Acknowledgements

We thank all study participants for their cooperation.

## Ethical Considerations

Ethical approval was obtained from the Institutional Ethics Committee (EC/OA-116/2020). The study was conducted in accordance with the principles outlined in the Declaration of Helsinki.

**Financial Disclosure**

This paper was Supported by the Indian Council of Medical Research (ICMR-STs).

**Competing Interests' Disclosure**

No conflict of interest was declared by authors.

**Authors' contributions**

Conceptualization: AC, JK, Methodology: MB & SM, Validation: AC, Data Curation, Formal Analysis: SM, Investigation: JK & SK, Writing–Original Draft Preparation: JK, Writing–Review & Editing: SM & AC, Visualization: AC, Supervision, Software: MB, Resources, Project Administration: SK.

**Writing Disclosure**

According to the writers, they wrote and prepared this work on their own, without using a professional writing service. The authors are the only ones who have contributed original work to the material.

**Data Availability Statement**

The corresponding author is readily available to provide the data that substantiates the findings of this study upon a reasonable request.

## References

- Kalairajan S, Durairaj KV, Malathy AR. A study on influence of iron deficiency anaemia over HbA<sub>1c</sub> levels. *Int J Adv Med*. 2019; 6(4):1095–100. <https://doi.org/10.18203/2349-3933.ijam20192586>
- Kim C, Bullard KM, Herman WH, Beckles GL. Association between iron deficiency and A1C Levels among adults without diabetes in the National Health and Nutrition Examination Survey, 1999–2006. *Diabetes Care*. 2010; 33(4):780–5. <https://doi.org/10.2337/dc09-0836>
- Nathan DM, Turgeon H, Regan S. Relationship between glycated haemoglobin levels and mean glucose levels over time. *Diabetologia*. 2007; 50:2239–44. <https://doi.org/10.1007/s00125-007-0803-0>
- Gillett MJ. International expert committee report on the role of the A1c assay in the diagnosis of diabetes. *Diabetes Care*. 2009; 32(7):1327. <https://doi.org/10.2337/dc09-9033>
- Bhardwaj K, Sharma SK, Rajpa N, Sachdev A. The effect of iron deficiency anaemia on haemoglobin A1c levels. *Ann Clin Lab Res*. 2016; 4(4):123. <https://doi.org/10.3343/alm.2012.32.1.17>
- DeMaeyer EA, Adiels-Tegman M. The prevalence of anaemia in the world. *World Health Stat Q*. 1985; 38(3):302–16. PMID: 3878044. (No doi available) PMID: 3878004.
- Anjana RM, Unnikrishnan R, Deepa M, Pradeepa R, Tandon N, Das AK, et al. Metabolic non-communicable disease health report of India: the ICMR-INDIAB national cross-sectional study (ICMR-INDIAB-17). *Lancet Diabetes Endocrinol*. 2023; 11(7):474–89. [https://doi.org/10.1016/S2213-8587\(23\)00119-5](https://doi.org/10.1016/S2213-8587(23)00119-5)
- Brooks AP, Metcalfe J, Day JL, Edwards MS. Iron deficiency and glycosylated haemoglobin A1. *Lancet*. 1980;316(8186):141. [https://doi.org/10.1016/S0140-6736\(80\)90019-7](https://doi.org/10.1016/S0140-6736(80)90019-7)
- Sinha N, Mishra TK, Singh T, Gupta N. Effect of iron deficiency anemia on hemoglobin A1c levels. *Ann Lab Med*. 2012; 32(1):17–22. <https://doi.org/10.3343/alm.2012.32.1.17>
- Christy AL, Manjrekar PA, Babu RP, Hegde A, Rukmini MS. Influence of iron deficiency anemia on hemoglobin A1c levels in diabetic individuals with controlled plasma glucose levels. *Iran Biomed J*. 2014; 18(2):88–91. <https://doi.org/10.6091/ibj.1257.2014>
- Hong JW, Ku CR, Noh JH, Ko KS, Rhee BD, Kim DJ. Association between the presence of iron deficiency anemia and hemoglobin A1c in Korean adults: the 2011–2012 Korea National Health and Nutrition Examination Survey. *Medicine (Baltimore)*. 2015; 94(20):e825. <https://doi.org/10.1097/MD.0000000000000825>
- Attard SM, Herring AH, Wang H, Howard AG, Thompson AL, Adair LS, et al. Implications of iron deficiency/anemia on the classification of diabetes using HbA<sub>1c</sub>. *Nutr Diabetes*. 2015; 5(6):e166. <https://doi.org/10.1038/nutd.2015.16>
- World Health Organization. WHO guideline on use of ferritin concentrations to assess iron status in populations. Geneva: WHO; 2020. (No DOI (official WHO document))
- Shanthi B, Revathy C, Devi AJ. Effect of iron deficiency on glycation of haemoglobin in nondiabetics. *J Clin Diagn Res*. 2013; 7(1):15–7. <https://doi.org/10.7860/JCDR/2012/4881.2659>
- Son JI, Rhee SY, Woo JT, Hwang JK, Chin SO, Chon S, et al. Hemoglobin A1c may be an inadequate diagnostic tool for diabetes mellitus in anemic subjects. *Diabetes Metab J*. 2013; 37(5):343–8. <https://doi.org/10.4093/dmj.2013.37.5.343>
- Koga M, Saito H, Mukai M, Matsumoto S, Kasayama S. Influence of iron metabolism indices on glycated haemoglobin but not glycated albumin levels in premenopausal women. *Acta Diabetol*. 2010; 47:65–9. <https://doi.org/10.1007/s00592-009-0120-1>
- Mitchell TR, Anderson D, Shepperd J. Iron deficiency, haemochromatosis, and glycosylated haemoglobin. *Lancet*. 1980; 316(8197):747. [https://doi.org/10.1016/S0140-6736\(80\)91969-8](https://doi.org/10.1016/S0140-6736(80)91969-8)
- Heyningen CV, Dalton RG. Glycosylated haemoglobin in iron-deficiency anaemia. *Lancet*. 1985; 325(8433):874. [https://doi.org/10.1016/s0140-6736\(85\)92234-2](https://doi.org/10.1016/s0140-6736(85)92234-2)
- Grossman A, Gafter-Gvili A, Schmilovitz-Weiss H, Koren-Morag N, Beloosesky Y, Weiss A. Association of glycated hemoglobin with hemoglobin levels in elderly nondiabetic subjects. *Eur J Intern Med*. 2016; 36:32–5. <https://doi.org/10.1016/j.ejim.2016.08.024>
- Alharbi KK, Al-Sulaiman AA, Khan IA, Alharbi FK, Khan AA. Effect of iron deficiency anemia on hemoglobin A1c in non-diabetic individuals: a systematic review and meta-analysis. *Diabetes Metab Syndr*. 2023; 17(1):102667. <https://doi.org/10.1016/j.dsx.2023.102667>
- Dutta D, Mukhopadhyay P, Saha D, Chowdhury S. Effects of iron deficiency anemia on hemoglobin A1c in diabetic individuals—a cross-sectional study from eastern India. *Diabetes Metab Syndr*. 2023;17(2):102712. <https://doi.org/10.1016/j.dsx.2023.102712>
- Zhang X, Wang Y, Li J, Xu X, Zhang Y, Xu Y, et al. Impact of red blood cell lifespan on HbA<sub>1c</sub> in type 2 diabetes mellitus. *Clin Chim Acta*. 2022; 530:143–9. PMID: 36294877. <https://doi.org/10.1016/j.cca.2022.02.016>
- Wang Y, Zhang X, Xu Y, Li J, Zhang Y, Xu X. Red blood cell lifespan and its influence on HbA<sub>1c</sub> levels in type 2 diabetes patients with controlled glycemia. *Diabetes Res Clin Pract*. 2024;199:110658. <https://doi.org/10.1016/j.diabres.2023.110658>
- Chaila MM, Gupta V, Ahmed S, Lio M, Taher J. Evaluation of four analytical methods for HbA<sub>1c</sub> measurement: a multicenter comparison study. *J Diabetes Sci Technol*. 2022;16(3):672–80. <https://doi.org/10.1177/1932296821997179>
- Ma Q, Li Y, Wang X, Liu X, Zhang W. Interpretation of HbA<sub>1c</sub> lies at the intersection of analytical and pathophysiological factors. *Exp Ther Med*. 2022; 23(6):211. <https://doi.org/10.3892/etm.2022.11243>
- Alharbi NS, Alahmadi SA, Almughamisi MS, et al. Effect of iron deficiency anemia on HbA<sub>1c</sub> levels: a systematic review and meta-analysis. *Diabetes Metab Syndr*. 2023;17(2):102597. <https://doi.org/10.1016/j.dsx.2023.102597>
- Nemeth E, Ganz T. The role of hepcidin in iron metabolism. *Acta Haematol*. 2009;122(2–3):78–86. <https://doi.org/10.1159/000243791>



28. Fernández-Real JM, McClain D, Manco M. Mechanisms linking glucose homeostasis and iron metabolism toward the onset and progression of type 2 diabetes. *Diabetes Care*. 2015;38(11):2169–76. <https://doi.org/10.2337/dc14-3082>
29. Goldstein DE, Little RR, Lorenz RA, et al. Tests of glycemia in diabetes. *Diabetes Care*. 2004;27(7):1761–73. <https://doi.org/10.2337/diacare.27.7.1761>.